Related Experiment Videos
[Randomized systemic chemotherapy using two or three drug combination for small cell lung cancer (SCLC)]
Gan No Rinsho. Japan Journal of Cancer Clinics
|February 1, 1984
Summary
A three-drug chemotherapy combination (ACNU, VCR, CPA) showed a higher response rate (60%) and improved survival in small cell lung cancer (SCLC) patients compared to two-drug regimens.
Area of Science:
- Medical Oncology
- Clinical Trials
- Pulmonology
Background:
- Small cell lung cancer (SCLC) remains a challenging diagnosis with limited treatment options.
- Optimizing chemotherapy regimens is crucial for improving patient outcomes in SCLC.
Purpose of the Study:
- To compare the efficacy of two-drug versus three-drug chemotherapy combinations in SCLC patients.
- To evaluate response rates, survival times, and safety profiles of different SCLC treatment regimens.
Main Methods:
- Sequential randomized trials were conducted comparing two-drug (ACNU/VCR, ADM/VCR) and three-drug (ACNU/CPA/VCR, ACNU/ADM/VCR) regimens.
- Patient response, median survival time, and performance status (PS) were assessed.
- Adverse events were monitored for safety evaluation.
Main Results:
- The three-drug combination achieved a response rate of 60.0% (15/25 cases), significantly higher than the 36.4% (8/22 cases) for the two-drug regimen.
- Median survival time was 9 months for the three-drug group versus 7 months for the two-drug group.
- Patients with better performance status (PS 0-1) demonstrated a significantly better prognosis (p=0.03), and no fatal side effects were observed.
Conclusions:
- The three-drug combination regimen, specifically ACNU, VCR, and CPA, is an active and effective treatment for SCLC.
- This regimen offers improved response rates and survival compared to standard two-drug approaches.
- The study highlights the importance of performance status in predicting SCLC patient prognosis.